

ASX MEDIA RELEASE

21 August 2023

Upcoming release of shares subject to escrow arrangements

Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”) advises, in accordance with ASX Listing Rule 3.10A, that 78,742,707 fully paid ordinary shares (CU6AD) and 9,768,220 unlisted options subject to escrow arrangements at the time that Clarity was admitted to the official list of ASX, will be released from escrow on 25 August 2023. The unlisted options are under the following ASX codes:

| | | |
|-------|-----------------------------|-----------|
| CU6AG | OPTION EXPIRING 15-DEC-2023 | 918,220 |
| CU6AH | OPTION EXPIRING 01-DEC-2024 | 3,000,000 |
| CU6AI | OPTION EXPIRING 18-DEC-2024 | 3,350,000 |
| CU6AJ | OPTION EXPIRING 10-MAY-2026 | 2,500,000 |

Further details of the escrow arrangements were detailed in section 10.4 of Clarity’s Prospectus dated 16 July 2021 and section 2.2 of Clarity’s Supplementary Prospectus dated 18 August 2021.

This announcement has been authorised for release by the Executive Chairman of Clarity Pharmaceuticals.

For more information, please contact:

Dr Alan Taylor
Executive Chairman
ataylor@claritypharm.com

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

www.claritypharmaceuticals.com